English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background HIV-infected patients harbouring a lamivudine-resistant virus, seem to take benefit from a continued lamivudine monotherapy, versus combined antiretroviral treatment (cART) interruption, since a reduced HIV replication is selected by the maintenance of lamivudine-related M184 mutation. The mid-term outcome of isolated lamivudine therapy in multidrug-resistant patients with very restricted therapeutic options, waiting for novel drug classes, is reported.

retrovirology

Lowering HIV fitness and replication rate by administration of lamivudine alone, in extensively resistant HIV-infected patients, as a "bridging" strategy towards optimized salvage regimens